Soleno Therapeutics (SLNO) Faces Investor Scrutiny Amid Disappointing VYKATÔ XR Starts, Discontinuations; Shares Down 26% -- Hagens Berman
PR Newswire —
SLNO Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, Nov. 7, 2025 /PRNewswire/ -- On November 5, 2025, investors in Soleno Therapeutics, Inc. (NASDAQ: SLNO) saw the price of their shares tumble $18.78 (-28%) after the company reported disappointing information...